These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25158034)

  • 1. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
    Moins-Teisserenc H; Daubord M; Clave E; Douay C; Félix J; Marie-Cardine A; Ram-Wolff C; Maki G; Beldjord K; Homyrda L; Michel L; Bensussan A; Toubert A; Bagot M
    J Invest Dermatol; 2015 Jan; 135(1):247-257. PubMed ID: 25158034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
    Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
    J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome.
    Vergnolle I; Douat-Beyries C; Boulinguez S; Rieu JB; Vial JP; Baracou R; Boudot S; Cazeneuve A; Chaugne S; Durand M; Estival S; Lablanche N; Nicolau-Travers ML; Tournier E; Lamant L; Vergez F
    Blood Adv; 2022 Mar; 6(6):1813-1825. PubMed ID: 34570200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
    Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
    Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome.
    Bouaziz JD; Remtoula N; Bensussan A; Marie-Cardine A; Bagot M
    Br J Dermatol; 2010 Jan; 162(1):123-8. PubMed ID: 19681856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.
    Bernengo MG; Novelli M; Quaglino P; Lisa F; De Matteis A; Savoia P; Cappello N; Fierro MT
    Br J Dermatol; 2001 Jan; 144(1):125-35. PubMed ID: 11167693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
    Horna P; Moscinski LC; Sokol L; Shao H
    Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
    Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.
    Ortonne N; Le Gouvello S; Tabak R; Marie-Cardine A; Setiao J; Berrehar F; Nghe-Tang A; Martin N; Bagot M; Bensussan A
    Exp Dermatol; 2012 Jun; 21(6):461-3. PubMed ID: 22621189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS).
    Jothishankar B; Venkataraman G; Goldberg RC; Abdulla F
    Ann Diagn Pathol; 2019 Dec; 43():151404. PubMed ID: 31629155
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome.
    Shareef MM; Elgarhy LH; Wasfy Rel-S
    Asian Pac J Cancer Prev; 2015; 16(13):5359-64. PubMed ID: 26225678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
    Suzuki SY; Ito K; Ito M; Kawai K
    J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
    Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
    J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.